Targeted Therapy for Cystic Fibrosis: Cystic Fibrosis Transmembrane Conductance Regulator Mutation-Specific Pharmacologic Strategies

Author： Rubenstein Ronald C.  

Publisher： Adis International

ISSN： 1177-1062

Source： Molecular Diagnosis & Therapy, Vol.10, Iss.5, 2006-01, pp. : 293-301

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cystic Fibrosis Transmembrane Conductance Regulator Recruitment to Phagosomes in Neutrophils

By  

Journal of Innate Immunity, Vol. 5, Iss. 3, 2013-03 ,pp. : 219-230

Karger

Access to resources Recommend Favorite

p.Leu636Pro mutation is associated with cystic fibrosis transmembrane conductance regulator‐related disorders (congenital bilateral absence of vas deferens)

By  

INTERNATIONAL JOURNAL OF UROLOGY, Vol. 22, Iss. 8, 2015-08 ,pp. : 803-804

John Wiley & Sons Inc

Access to resources Recommend Favorite

Editorial Comment to p.Leu636Pro mutation is associated with cystic fibrosis transmembrane conductance regulator‐related disorders (congenital bilateral absence of vas deferens)

By  

INTERNATIONAL JOURNAL OF UROLOGY, Vol. 22, Iss. 8, 2015-08 ,pp. : 804-804

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparative computational analysis of cystic fibrosis transmembrane conductance regulator protein to treat lung infections

By Subhashini R.  

International Journal of Medical Engineering and Informatics, Vol. 4, Iss. 4, 2012-11 ,pp. : 351-361

Inderscience Publishers

Access to resources Recommend Favorite

Sperm cystic fibrosis transmembrane conductance regulator expression level is relevant to fecundity of healthy couples

By  

ANDROLOGIA (ELECTRONIC), Vol. 50, Iss. 2, 2018-03 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite